Mylan has snapped up Strides Arcolab's injectables arm, Agila Specialties, for $1.6 billion, plus $250 million in additional conditional payments, a transaction, which though seen as expensive, is expected to fast-track Mylan's approach towards becoming a top-three global player in the injectables space.
Sample this: Mylan-Agila combined will have more than 700 marketed injectables products and a global pipeline of over 350 injectables...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?